Short duration of AcPAS treatment accelerates MEMRI signal decline but not manganese washout
Aditya N Bade 1 , Biyun Zhou 2 , JoEllyn McMillan 1 , Prabagaran Narayanasamy 1 , Ram Veerubhotla 1 , Howard E Gendelman 1 , Michael D Boska 1,3 , and Yutong Liu 1,3
Pharmacology and Experimental neuroscience,
University of Nebraska Medical Center, Omaha, NE, United
of Anesthesiology, Tongji Medical College, Huanzhong
University of Science and Technology, China,
of Radiology, University of Nebraska Medical Center,
Omaha, NE, United States
Quantitative manganese (Mn2+) uptake provides measures
of neuronal and glial activities making MEMRI a valuable
test for assessment of neurodegenerative processes.
However, the prolonged half-life of Mn2+ in brain (5174
days) limits serial quantitative MR assessments.
Previous studies have suggested that
N-acetyl-para-aminosalicylic acid (AcPAS), a chelater of
manganese may provide an answer. Thus, we determined
whether AcPAS could affect Mn2+ enhancement decline and
permit its frequent administration for longitudinal
studies, PBS used as control. The results suggest that
the chelation by AcPAS interfere with the interaction of
water molecules and Mn2+ ions, and therefore suppresses
Mn2+ T1 shortening effect.
This abstract and the presentation materials are available to members only;
a login is required.